Acadia Pharmaceuticals | ACAD - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Acadia Pharmaceuticals USD 0 4.12M 2024-09
ALKERMES USD 20.89M 8.62M 2026-03
Alnylam Pharmaceuticals USD 69.29M 60.05M 2026-03
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 14.96M 12.18M 2026-03
Bristol-Myers Squibb USD 411M 21M 2026-03
Cara Therapeutics -89.64M 128.67M 2025-12
Corcept Therapeutics USD 814.88M 809.46M 2026-03
Cytokinetics USD 33.34M 3M 2026-03
Eisai JPY 1.55B 117M 2026-03
Eli Lilly USD 114.7M 134.3M 2025-09
Incyte USD 569K 13K 2026-03
J&J USD 43M 25M 2026-03
Moderna USD 11.49B 36B 2026-03
Neurocrine Biosciences USD 1.1M 0 2024-03
Pfizer USD 671M 40M 2026-03
Prothena USD 349.89M 347.27M 2026-03
PTC Therapeutics USD 2.87B 2.82B 2026-03
Sarepta Therapeutics USD 20.84M 13.28M 2025-12
Ultragenyx Pharmaceutical USD 21M 2M 2026-03
Vanda Pharmaceuticals -1.37B 1.97B 2025-12
Vertex Pharmaceuticals USD 3.3M 0 2025-12